Table 1.
Characteristics of the 61 evaluated patients
| Characteristics | Value |
|---|---|
| Age (years) | |
| Median | 62 |
| Range | 36–82 |
| Sex (number of patients) | |
| Female | 24 |
| Male | 37 |
| Weight (kg) | |
| Median | 77 |
| Range | 49–118 |
| Number of metastatic sites | |
| Median | 2 |
| Range | 1–4 |
| KRAS status | |
| Wild-type | 42 (69%) |
| Mutations | 18 (30%) |
| Unknown | 1 (∼1%) |
| Number of treatments per patient | |
| Median | 8 |
| Range | 4–28 |
| Number of examinations | |
| Total | 203 |
| Median | 3 |
| Range | 2–7 |
| Scanner (number of patients) | |
| Philips Gemini dual slice | 56 |
| Philips TF 16 slice | 5 |
| Treatment received after progression to the protocol-treatment (irinotecan + cetuximab) | |
| No treatment | 30 |
| Cetuximab + irinotecan + sunitinib | 23 |
| Cetuximab + irinotecan + bevazicumab | 3 |
| Other | 5 |